Laurence Zitvogel - Curriculum Vitae#
Current positions:
Full Professor, Immunology Biology, Medical School, Paris-Saclay, France
Scientific Director of OncoImmunology, Gustave Roussy
Director of U1015 INSERM : Label since 2002
Co-Director CIC BT507 Biotherapies of Cancer : Label since 2004
Research Director, sponsored team by LIGUE contre le Cancer: Label since 2002
Title of the expertise: Tumor Immunology and Cancer Immunotherapy
Career Summary:
Professor Laurence Zitvogel, clinical oncologist and research director, has been actively contributing to the field of cancer immunology and immunotherapy since 1992. She brought together basic and translational research, including the design of cancer therapies through combined animal studies and Phase I patient trials. Her expertise is mainly focused on dendritic cell and innate effector biology and relevance during tumour development as well as exosome-based vaccine designs. She pioneered the concept of immunogenic cell death and showed that chemotherapy, radiotherapy and inhibitors of tyrosine kinase mediate their tumoricidal activity, at least partly through the immune system.
She recently uncovered the role of gut microbiota in regulating anti-tumor immunity during therapy with cyclophosphamide and ipilimumab. She has received numerous Prizes and awards from the National Academies (of medicine or Sciences), from INSERM (Translational Research Grand Prize), was nominated “Chevalier à l’Ordre de la Légion d’honneur” by the Health MMinistry, and member of the National Academy of Medicine and of the European Academy of Cancer Sciences. Her H citation factor is 98, with >380 publications on PubMed, and ranked by LabTimes Magazine in June 2013 as the "first" female immunologist in Europe (based on 111 papers published from 2005-2011with 7598 citations over this time) and by Thomson Reuters as one of the three top French scientists of the last 5 years. Currently she directs the Research Department of ImmunoOncology at Gustave Roussy Cancer Center, Grand-Paris, France, and the TORINO-LUMIERE RHU microbiome-cancer network (10 million euros).
